Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives

Figure 3

Clinical benefits achieved in the IMPROVE-IT trial (primary end point was a combination of CV death/major CV event and nonfatal stroke; nonsignificant. There was no difference in CV death and unstable angina).